RxDoctor Payments Data

Lindsay Handley

Nurse Practitioner · Cordova, ALNPI 1912418005

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 64 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$529
  • AstraZeneca$169
  • Novo Nordisk$120
  • Lilly USA, LLC$82
  • Dexcom, Inc.$58
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$33
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$1,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107 in reported general payments places this provider in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$18,352
Medicare patients
64
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$19,833
MounjaroTirzepatide14$14,558
Albuterol Sulfate HfaAlbuterol Sulfate46$1,137
Fluticasone Propionate22$374
Rosuvastatin Calcium18$335
Buspirone Hcl19$278
Doxycycline Hyclate15$183
Levocetirizine Dihydrochloride13$181
Lisinopril20$172
Levothyroxine Sodium13$165
Potassium Chloride14$154
Pantoprazole Sodium13$145
Tamsulosin Hcl12$140
Atorvastatin Calcium12$126
Metoprolol Succinate12$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$169$19,83318 claims
Lilly USA, LLCMounjaro$82$14,55814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Cordova

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →